AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2– advanced breast cancer

por Bardia, Aditya, Cortes, Javier, Hurvitz, Sara A., Delaloge, Suzette, Iwata, Hiroji, Shao, Zhi-Ming, Kanagavel, Dheepak, Cohen, Patrick, Liu, Qianying, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, O’Shaughnessy, Joyce
Publicado 2022

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

por Bardia, Aditya, Chandarlapaty, Sarat, Linden, Hannah M., Ulaner, Gary A., Gosselin, Alice, Cartot-Cotton, Sylvaine, Cohen, Patrick, Doroumian, Séverine, Paux, Gautier, Celanovic, Marina, Pelekanou, Vasiliki, Ming, Jeffrey E., Ternès, Nils, Bouaboula, Monsif, Lee, Joon Sang, Bauchet, Anne-Laure, Campone, Mario
Publicado 2022